Publicacións (84) Publicacións de Alvaro Mena de Cea

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial

    Journal of Clinical Medicine, Vol. 13, Núm. 17

  3. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

  4. Safety and efficacy of personalised versus standard dosing of linezolid in patients with sepsis (SePkLin): a pragmatic, multicentre, randomised, controlled and superiority clinical trial protocol

    BMJ open, Vol. 14, Núm. 10, pp. e087465

  5. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

  6. Stratification tools in the follow-up of people living with HIV, are they necessary and applicable?

    Farmacia Hospitalaria

2023

  1. Lipid profile changes associated with antiretroviral therapies in a real-world cohort

    Farmacia Hospitalaria, Vol. 47, Núm. 5, pp. 210-217

  2. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e652-e660

  3. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 5, pp. 382-396

  4. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort

    PLoS ONE, Vol. 17, Núm. 11 November

  2. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

  3. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  4. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

  5. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  6. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV

    AIDS, Vol. 36, Núm. 5, pp. 691-695

  7. Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV

    Frontiers in immunology, Vol. 13, pp. 873408

2021

  1. Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors

    HIV Medicine, Vol. 22, Núm. 1, pp. 47-53

  2. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  3. Central nervous system disorders in HIV-infected individuals using distinct antiretroviral drugs

    AIDS Reviews, Vol. 23, Núm. 4, pp. 214-225